This summer, we saw remarkable, bipartisan progress on addressing rising health care costs — an issue voters consistently rank as ‘most important’.
The challenge for lawmakers right now is twofold: find effective solutions to make healthcare more affordable for all Americans without reducing access to treatments.
While our healthcare system often seems like a tangled knot of misaligned incentives and bureaucracy, there are most certainly bipartisan solutions Congress can implement to achieve this dual goal.
The issue is of particular concern for the mental health community. Millions of Americans confront mental illness every day and approximately one in six use some form of psychiatric medication. For those battling addiction, medication can sometimes mean the difference between success and failure.
Medication is not a one-size-fits-all solution. Prescriptions must be monitored and adjusted as treatment progresses. It’s why organizations such as Mental Health America consistently oppose policies seeking to restrict access to new medications.
Fortunately, many practical solutions were already explored and are waiting for a champion to take them over the finish line.
Reforms like passing on some of the rebates in Medicare Part D will realign incentives throughout the whole system to bring down prices, all while providing actual savings at the pharmacy.
The plan is simple enough — forcing insurance companies and pharmacy benefit managers (massive private “middlemen” between drug companies and insurers) to pass on drug rebates to patients at the point of sale.
For patients, passing on rebates would provide immediate relief. It is estimated that sharing a portion of rebates with diabetes patients on Medicare could save up to $20 billion over the next 10 years.
Most importantly, this plan addresses the rising cost of prescription drugs.
Currently, pharmacy benefit managers pocket rebates, claiming they spread the cost of drugs throughout premiums and other patient fees. So not only are patients not receiving the savings intended for them, but the cost of medicine is rising.
Pharmacy benefit managers and insurers are incentivized to maximize the number of rebates they can receive. And since rebates are used for the most expensive drugs, this means benefit managers are also incentivized to keep drug prices high -- or steer patients toward high-priced drugs.
Both practices increase costs for families across the nation. Removing incentives would help patients find effective and affordable treatment options.
I look forward to members of Congress from both sides of the aisle addressing this problem. Rebate reform is the best place to start.